CXM Financial Facts
Research and development: 108.67KLoss from operations: -1.19M
See Full Income Statement
Accrued liabilities: 967.92K
Total stockholders' equity: -3.36M
See Full Balance Sheet
Cardium Therapeutics, Inc. (CXM) Earnings
|
Expand Research on CXM
| Next EPS Date | 9/9/26 | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +26.9% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +2.2% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
9/9/26  |
Q227 | N/A | $0.12 | N/A | N/A | $215.56M | = | N/A | N/A | ||
| 6/3/26 | Q127 | $0.11 | $0.10 | +$0.01 | $219.5M | $215.3M | = |  | | Details | |
| 3/11/26 | Q426 | $0.13 | $0.09 | +$0.04 | $220.6M | $215.51M | = | | | Details | |
| 12/3/25 | Q326 | $0.12 | $0.09 | +$0.03 | $219.1M | $209.56M | = | | | Details | |
| 9/3/25 |
Q226 | N/A | $0.10 | N/A | N/A | $205.4M | = | N/A | N/A | ||
| 6/4/25 | Q126 | $0.12 | $0.10 | +$0.02 | $205.5M | $201.88M | = | | | Details | |
| 3/12/25 | Q425 | $0.10 | $0.07 | +$0.03 | $202.5M | $200.52M | = | | | Details | |
| 12/4/24 | Q325 | $0.10 | $0.08 | +$0.02 | $200.7M | $196.48M | = | | | Details |
